Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Larger, Phase 2 study of NYX-2925 in Subjects with Fibromyalgia

Trial Profile

A Larger, Phase 2 study of NYX-2925 in Subjects with Fibromyalgia

Planning
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2018

At a glance

  • Drugs NYX 2925 (Primary)
  • Indications Fibromyalgia
  • Focus Therapeutic Use
  • Sponsors Aptinyx
  • Most Recent Events

    • 13 Dec 2019 Indexed, dosage form as capsule, based on previous phase II pilot study info. (287591-single blind study and placebo was given as capsules).Please cross-check with registry or other sources for confirmation.
    • 13 Dec 2018 New trial record
    • 03 Dec 2018 According to an Aptinyx media release, based on positive interim data from pilot, phase II study (NCT03249103), the company expects to initiate this larger phase 2 study in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top